Neoadjuvant Immunotherapy in Brain Metastases

Summary

Neoadjuvant Immunotherapy in Brain Metastases is a clinical trial^[1].

Key Facts

• Neoadjuvant Immunotherapy in Brain Metastases is in the country of United States^[2].
• Neoadjuvant Immunotherapy in Brain Metastases's instance of is recorded as clinical trial^[3].
• Neoadjuvant Immunotherapy in Brain Metastases's start time is recorded as +2020-07-31T00:00:00Z^[4].
• Neoadjuvant Immunotherapy in Brain Metastases's end time is recorded as +2023-01-31T00:00:00Z^[5].
• Neoadjuvant Immunotherapy in Brain Metastases's contributor to the creative work or subject is recorded as Bristol-Myers Squibb^[6].
• Neoadjuvant Immunotherapy in Brain Metastases's contributor to the creative work or subject is recorded as Duke University^[7].
• Neoadjuvant Immunotherapy in Brain Metastases's main subject is recorded as renal pelvis and ureter transitional cell cancer^[8].
• Neoadjuvant Immunotherapy in Brain Metastases's main subject is recorded as nivolumab^[9].
• Neoadjuvant Immunotherapy in Brain Metastases's main subject is recorded as ipilimumab^[10].
• Neoadjuvant Immunotherapy in Brain Metastases's number of participants is recorded as {'unit': '1', 'amount': '+40'}^[11].
• Neoadjuvant Immunotherapy in Brain Metastases's title is recorded as A Randomized Phase II Trial of Surgery and Stereotactic Radiosurgery With and Without Neoadjuvant Nivolumab and Ipilimumab in Patients With Surgically-resectable, Solid Tumor Brain Metastases^[12].
• Neoadjuvant Immunotherapy in Brain Metastases's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[13].
• Neoadjuvant Immunotherapy in Brain Metastases's ClinicalTrials.gov ID is recorded as NCT04434560^[14].
• Neoadjuvant Immunotherapy in Brain Metastases's research intervention is recorded as nivolumab^[15].
• Neoadjuvant Immunotherapy in Brain Metastases's research intervention is recorded as ipilimumab^[16].
• Neoadjuvant Immunotherapy in Brain Metastases's clinical trial phase is recorded as phase II clinical trial^[17].
• Neoadjuvant Immunotherapy in Brain Metastases's research site is recorded as Duke University Medical Center^[18].
• Neoadjuvant Immunotherapy in Brain Metastases's research subject recruitment status is recorded as not yet recruiting^[19].
• Neoadjuvant Immunotherapy in Brain Metastases's study type is recorded as interventional study^[20].